Search results
Results From The WOW.Com Content Network
Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient. [ 30 ] Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.
Head and neck cancer is a general term encompassing multiple cancers that can develop in the head and neck region. These include cancers of the mouth, tongue, gums and lips ( oral cancer ), voice box ( laryngeal ), throat ( nasopharyngeal , oropharyngeal , [ 1 ] hypopharyngeal ), salivary glands , nose and sinuses .
Felzartamab (MOR202)is a humanized monoclonal antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease affecting the kidneys. [2] In 2017, MorphoSys entered into a regional licensing agreement with I-Mab Biopharma to develop and commercialize Felzartamab (called TJ202 by I-Mab) in ...
No cancer therapy is without the risk of side effects. Neutron therapy is a very powerful nuclear scalpel that has to be utilized with exquisite care. For instance, some of the most remarkable cures it has been able to achieve are with cancers of the head and neck. Many of these cancers cannot effectively be treated with other therapies.
HPV+OPC presents in one of four ways: as an asymptomatic abnormality in the mouth found by the patient or a health professional such as a dentist; with local symptoms such as pain or infection at the site of the tumor; with difficulties of speech, swallowing, and/or breathing; or as a swelling in the neck (if the cancer has spread to lymph nodes).
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
The cost of Factor VIII and similar clotting factors has been described as "highly expensive". [21] The cost of the clotting factors is 80% of all medical costs for people with hemophilia. [ 23 ] They are so expensive that gene therapy for haemophilia might be less expensive, especially for people with severe hemophilia.
A prospective payment system (PPS) is a term used to refer to several payment methodologies for which means of determining insurance reimbursement is based on a predetermined payment regardless of the intensity of the actual service provided.